TransMedics Group, Inc. (NASDAQ:TMDX) Stake Boosted by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 1,602.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,359 shares of the company's stock after purchasing an additional 4,103 shares during the period. Tower Research Capital LLC TRC's holdings in TransMedics Group were worth $272,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of TMDX. Virtu Financial LLC acquired a new stake in shares of TransMedics Group during the 3rd quarter worth approximately $436,000. Wilmington Savings Fund Society FSB acquired a new stake in TransMedics Group in the third quarter worth $149,000. Principal Financial Group Inc. lifted its stake in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company's stock valued at $31,759,000 after buying an additional 146,115 shares during the last quarter. APEIRON CAPITAL Ltd acquired a new position in shares of TransMedics Group during the fourth quarter valued at $468,000. Finally, Fiduciary Alliance LLC bought a new position in shares of TransMedics Group during the fourth quarter worth about $247,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TMDX. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Piper Sandler reaffirmed an "overweight" rating and set a $105.00 price target (up previously from $90.00) on shares of TransMedics Group in a report on Tuesday, April 29th. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $124.20.

TransMedics Group Stock Performance

TMDX opened at $89.98 on Friday. The business has a 50 day moving average price of $76.02 and a two-hundred day moving average price of $76.35. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of 95.72 and a beta of 2.14. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.